Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype

Anita Hanyecz, Suzanne E. Berlo, S. Szántó, Chris P M Broeren, Katalin Mikecz, Tibor T. Glant

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Objective. To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). Methods. PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type H collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CH, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. Results. A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. Conclusion. DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.

Original languageEnglish
Pages (from-to)1665-1676
Number of pages12
JournalArthritis and Rheumatism
Volume50
Issue number5
DOIs
Publication statusPublished - May 2004

Fingerprint

Innate Immunity
Proteoglycans
Arthritis
Experimental Arthritis
Phenotype
Cartilage
Freund's Adjuvant
Aggrecans
Complex Mixtures
Antigens
Immunization
Th1-Th2 Balance
Ego
Incidence
dimethyldioctadecylammonium
Autoimmunity
Sheep
Swine
Collagen

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype. / Hanyecz, Anita; Berlo, Suzanne E.; Szántó, S.; Broeren, Chris P M; Mikecz, Katalin; Glant, Tibor T.

In: Arthritis and Rheumatism, Vol. 50, No. 5, 05.2004, p. 1665-1676.

Research output: Contribution to journalArticle

Hanyecz, Anita ; Berlo, Suzanne E. ; Szántó, S. ; Broeren, Chris P M ; Mikecz, Katalin ; Glant, Tibor T. / Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype. In: Arthritis and Rheumatism. 2004 ; Vol. 50, No. 5. pp. 1665-1676.
@article{82604d9f2aa1420a9d8984dece754bc4,
title = "Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype",
abstract = "Objective. To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). Methods. PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type H collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CH, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. Results. A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100{\%} incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. Conclusion. DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.",
author = "Anita Hanyecz and Berlo, {Suzanne E.} and S. Sz{\'a}nt{\'o} and Broeren, {Chris P M} and Katalin Mikecz and Glant, {Tibor T.}",
year = "2004",
month = "5",
doi = "10.1002/art.20180",
language = "English",
volume = "50",
pages = "1665--1676",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype

AU - Hanyecz, Anita

AU - Berlo, Suzanne E.

AU - Szántó, S.

AU - Broeren, Chris P M

AU - Mikecz, Katalin

AU - Glant, Tibor T.

PY - 2004/5

Y1 - 2004/5

N2 - Objective. To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). Methods. PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type H collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CH, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. Results. A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. Conclusion. DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.

AB - Objective. To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). Methods. PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type H collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CH, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. Results. A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. Conclusion. DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.

UR - http://www.scopus.com/inward/record.url?scp=2342497178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342497178&partnerID=8YFLogxK

U2 - 10.1002/art.20180

DO - 10.1002/art.20180

M3 - Article

VL - 50

SP - 1665

EP - 1676

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -